Brokers review AstraZeneca after Q2 2010 report.

(ADPnews) - Jul 30, 2010 - Deutsche Bank, S&P Equity Research and Credit Suisse have reviewed their stance on Anglo-Swedish AstraZeneca (LON:AZN, STO:AZN) after the pharma major yesterday posted better-than-expected results for the second quarter of 2010.

Deutsche Bank has upgraded its share price target on AstraZeneca to GBP 33 from GBP 30 and S&P -- to GBP 28.50 from GBP 27.50. The brokers have maintained their ratings at "hold" and "sell", respectively.

Credit Suisse has reaffirmed its "neutral" recommendation with a price target of GBP 31 on AstraZeneca. The broker has made minor changes in its estimates for the company and now expects core earnings per …